NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus MSCs in Patients with Osteoarthritis
pharmaceutical investing Cynata CYP-001 Stem Cell Therapy Meets All Safety and Efficacy Endpoints in Phase 1 Trial in GvHD
Red Metals Corp Invites Shareholders and Investment Community to Visit Them at Booth 2538 at PDAC 2026 in Toronto, March 1-4
Silver Hammer Closes CDN$3,913,617 Non-Brokered Private Placement Pursuant to Listed Issuer Exemption
